Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uveitis | 65 | 2024 | 375 | 11.420 |
Why?
|
Cytomegalovirus Retinitis | 22 | 2020 | 58 | 3.490 |
Why?
|
Visual Acuity | 59 | 2024 | 2530 | 3.330 |
Why?
|
Scleritis | 16 | 2021 | 100 | 3.290 |
Why?
|
Uveitis, Anterior | 15 | 2023 | 101 | 3.280 |
Why?
|
Cataract | 27 | 2024 | 834 | 3.190 |
Why?
|
AIDS-Related Opportunistic Infections | 18 | 2020 | 657 | 3.050 |
Why?
|
Panuveitis | 11 | 2023 | 32 | 3.030 |
Why?
|
Uveitis, Intermediate | 9 | 2021 | 17 | 2.930 |
Why?
|
Fluocinolone Acetonide | 15 | 2020 | 36 | 2.700 |
Why?
|
Glucocorticoids | 34 | 2023 | 2107 | 2.640 |
Why?
|
Cataract Extraction | 15 | 2024 | 481 | 2.380 |
Why?
|
Uveitis, Posterior | 10 | 2020 | 44 | 2.380 |
Why?
|
Vision Disorders | 23 | 2024 | 1058 | 2.300 |
Why?
|
Immunosuppressive Agents | 28 | 2023 | 4149 | 1.840 |
Why?
|
Macular Edema | 12 | 2023 | 359 | 1.660 |
Why?
|
Eye Infections, Viral | 4 | 2023 | 57 | 1.420 |
Why?
|
Eye Diseases | 11 | 2020 | 669 | 1.340 |
Why?
|
Blindness | 11 | 2020 | 617 | 1.290 |
Why?
|
Pemphigoid, Benign Mucous Membrane | 8 | 2015 | 123 | 1.240 |
Why?
|
Glaucoma | 17 | 2023 | 1159 | 1.200 |
Why?
|
Behcet Syndrome | 4 | 2021 | 84 | 1.110 |
Why?
|
Trachoma | 4 | 2019 | 29 | 1.050 |
Why?
|
Drug Implants | 17 | 2020 | 244 | 1.030 |
Why?
|
Tuberculosis, Ocular | 5 | 2022 | 9 | 1.020 |
Why?
|
Azathioprine | 3 | 2023 | 353 | 0.970 |
Why?
|
Ophthalmology | 5 | 2020 | 508 | 0.880 |
Why?
|
Vitreous Body | 6 | 2020 | 389 | 0.850 |
Why?
|
Prednisolone | 3 | 2017 | 334 | 0.810 |
Why?
|
Retinal Diseases | 4 | 2020 | 683 | 0.800 |
Why?
|
Acquired Immunodeficiency Syndrome | 9 | 2014 | 2232 | 0.790 |
Why?
|
Mycophenolic Acid | 5 | 2023 | 343 | 0.770 |
Why?
|
Fluprednisolone | 2 | 2017 | 6 | 0.760 |
Why?
|
Anti-Inflammatory Agents | 8 | 2019 | 1790 | 0.760 |
Why?
|
Visually Impaired Persons | 5 | 2020 | 81 | 0.740 |
Why?
|
Antiretroviral Therapy, Highly Active | 14 | 2020 | 1873 | 0.710 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 401 | 0.680 |
Why?
|
Fluorometholone | 1 | 2018 | 5 | 0.680 |
Why?
|
Trichiasis | 1 | 2018 | 5 | 0.670 |
Why?
|
Fluorescein Angiography | 9 | 2023 | 940 | 0.660 |
Why?
|
Iontophoresis | 1 | 2018 | 74 | 0.640 |
Why?
|
Remission, Spontaneous | 2 | 2016 | 382 | 0.630 |
Why?
|
Incidence | 40 | 2023 | 20947 | 0.630 |
Why?
|
Intraocular Pressure | 11 | 2020 | 1270 | 0.630 |
Why?
|
Triamcinolone Acetonide | 2 | 2018 | 101 | 0.620 |
Why?
|
Retinal Detachment | 7 | 2023 | 411 | 0.610 |
Why?
|
Diabetic Retinopathy | 7 | 2022 | 1210 | 0.580 |
Why?
|
Prevalence | 35 | 2021 | 15226 | 0.570 |
Why?
|
Dexamethasone | 3 | 2023 | 1951 | 0.510 |
Why?
|
Eye Infections, Bacterial | 4 | 2021 | 235 | 0.510 |
Why?
|
Retrospective Studies | 60 | 2024 | 77449 | 0.500 |
Why?
|
Remission Induction | 2 | 2019 | 2386 | 0.480 |
Why?
|
Vision, Low | 5 | 2018 | 168 | 0.460 |
Why?
|
Tomography, Optical Coherence | 12 | 2023 | 2657 | 0.450 |
Why?
|
Developing Countries | 3 | 2019 | 2815 | 0.450 |
Why?
|
Models, Structural | 1 | 2013 | 361 | 0.450 |
Why?
|
Humans | 175 | 2024 | 744343 | 0.450 |
Why?
|
Diagnostic Techniques, Ophthalmological | 2 | 2020 | 245 | 0.440 |
Why?
|
Conjunctival Diseases | 4 | 2024 | 122 | 0.440 |
Why?
|
Ocular Hypotension | 1 | 2012 | 22 | 0.430 |
Why?
|
Risk Factors | 47 | 2023 | 72290 | 0.420 |
Why?
|
Ophthalmia, Sympathetic | 2 | 2023 | 16 | 0.420 |
Why?
|
Retinal Necrosis Syndrome, Acute | 2 | 2023 | 21 | 0.420 |
Why?
|
Adult | 90 | 2024 | 214055 | 0.410 |
Why?
|
Refractive Errors | 3 | 2020 | 142 | 0.410 |
Why?
|
Middle Aged | 84 | 2023 | 213383 | 0.400 |
Why?
|
Male | 103 | 2023 | 350118 | 0.400 |
Why?
|
Prednisone | 9 | 2019 | 1574 | 0.400 |
Why?
|
Methotrexate | 5 | 2023 | 1727 | 0.390 |
Why?
|
Follow-Up Studies | 30 | 2023 | 39050 | 0.380 |
Why?
|
Female | 105 | 2023 | 380194 | 0.380 |
Why?
|
India | 7 | 2021 | 2197 | 0.380 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 595 | 0.380 |
Why?
|
Cohort Studies | 25 | 2023 | 40561 | 0.370 |
Why?
|
Eye Infections | 2 | 2022 | 64 | 0.360 |
Why?
|
Macula Lutea | 2 | 2023 | 151 | 0.360 |
Why?
|
Chorioretinitis | 2 | 2020 | 43 | 0.360 |
Why?
|
Choroidal Neovascularization | 1 | 2013 | 343 | 0.360 |
Why?
|
Endophthalmitis | 2 | 2010 | 262 | 0.360 |
Why?
|
Anterior Chamber | 4 | 2017 | 197 | 0.340 |
Why?
|
Glaucoma Drainage Implants | 1 | 2010 | 116 | 0.330 |
Why?
|
HIV Infections | 8 | 2020 | 16718 | 0.320 |
Why?
|
Publications | 1 | 2011 | 195 | 0.320 |
Why?
|
Retinal Vasculitis | 3 | 2020 | 42 | 0.320 |
Why?
|
Herpes Simplex | 2 | 2023 | 470 | 0.310 |
Why?
|
Macular Degeneration | 7 | 2020 | 980 | 0.310 |
Why?
|
Adolescent | 40 | 2021 | 85781 | 0.300 |
Why?
|
Antimetabolites | 2 | 2023 | 125 | 0.300 |
Why?
|
Epidemiologic Methods | 3 | 2011 | 1364 | 0.300 |
Why?
|
Inflammation | 17 | 2023 | 10638 | 0.300 |
Why?
|
Corneal Ulcer | 2 | 2019 | 169 | 0.290 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2015 | 4420 | 0.290 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1411 | 0.290 |
Why?
|
Antitubercular Agents | 5 | 2022 | 1320 | 0.290 |
Why?
|
Treatment Outcome | 30 | 2024 | 63114 | 0.290 |
Why?
|
Visual Fields | 6 | 2015 | 1047 | 0.290 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2219 | 0.280 |
Why?
|
Neoplasms | 4 | 2023 | 21683 | 0.280 |
Why?
|
Cytomegalovirus Infections | 2 | 2023 | 820 | 0.260 |
Why?
|
CD4 Lymphocyte Count | 10 | 2014 | 2559 | 0.260 |
Why?
|
Cyclosporine | 2 | 2023 | 786 | 0.260 |
Why?
|
Phacoemulsification | 2 | 2024 | 149 | 0.260 |
Why?
|
Anti-Retroviral Agents | 2 | 2020 | 1715 | 0.260 |
Why?
|
Uveomeningoencephalitic Syndrome | 2 | 2020 | 19 | 0.250 |
Why?
|
Choroid Diseases | 1 | 2005 | 66 | 0.250 |
Why?
|
Ocular Hypertension | 2 | 2017 | 198 | 0.250 |
Why?
|
Adrenal Cortex Hormones | 2 | 2022 | 1855 | 0.250 |
Why?
|
Environmental Monitoring | 1 | 2011 | 1414 | 0.250 |
Why?
|
Ethiopia | 3 | 2022 | 495 | 0.240 |
Why?
|
Refraction, Ocular | 3 | 2014 | 182 | 0.240 |
Why?
|
Immunoglobulin G | 2 | 2013 | 4560 | 0.230 |
Why?
|
Visual Perception | 1 | 2012 | 1420 | 0.230 |
Why?
|
Aged | 47 | 2021 | 163280 | 0.230 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2023 | 36 | 0.230 |
Why?
|
Decision Support Techniques | 1 | 2013 | 1956 | 0.220 |
Why?
|
Alkylating Agents | 1 | 2023 | 139 | 0.220 |
Why?
|
Tissue and Organ Procurement | 2 | 2021 | 896 | 0.220 |
Why?
|
Antibodies, Monoclonal | 4 | 2015 | 9274 | 0.220 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 10943 | 0.210 |
Why?
|
Research Design | 4 | 2011 | 5987 | 0.200 |
Why?
|
Case-Control Studies | 5 | 2021 | 21746 | 0.200 |
Why?
|
Aged, 80 and over | 24 | 2021 | 57776 | 0.200 |
Why?
|
Age Distribution | 9 | 2021 | 2902 | 0.200 |
Why?
|
Antiviral Agents | 10 | 2023 | 2987 | 0.200 |
Why?
|
Young Adult | 23 | 2021 | 56430 | 0.200 |
Why?
|
Double-Blind Method | 5 | 2018 | 12026 | 0.200 |
Why?
|
Intravitreal Injections | 5 | 2023 | 344 | 0.190 |
Why?
|
Herpes Zoster | 1 | 2023 | 264 | 0.190 |
Why?
|
Choroiditis | 1 | 2020 | 12 | 0.190 |
Why?
|
Prospective Studies | 21 | 2023 | 53288 | 0.190 |
Why?
|
Sex Distribution | 7 | 2021 | 2297 | 0.190 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2716 | 0.190 |
Why?
|
Corneal Dystrophies, Hereditary | 1 | 2021 | 81 | 0.190 |
Why?
|
Child | 27 | 2024 | 77709 | 0.180 |
Why?
|
Ophthalmic Solutions | 2 | 2019 | 317 | 0.180 |
Why?
|
Corneal Opacity | 2 | 2018 | 60 | 0.180 |
Why?
|
Leprosy | 3 | 2019 | 124 | 0.180 |
Why?
|
Toxoplasmosis, Ocular | 1 | 2019 | 29 | 0.180 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2282 | 0.180 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 1 | 2021 | 109 | 0.170 |
Why?
|
United States | 24 | 2023 | 69872 | 0.170 |
Why?
|
Sjogren's Syndrome | 1 | 2021 | 233 | 0.170 |
Why?
|
Neglected Diseases | 1 | 2019 | 64 | 0.170 |
Why?
|
Child, Preschool | 14 | 2021 | 41006 | 0.160 |
Why?
|
Tonometry, Ocular | 3 | 2015 | 237 | 0.160 |
Why?
|
Sickness Impact Profile | 3 | 2014 | 302 | 0.150 |
Why?
|
Ganciclovir | 3 | 2023 | 258 | 0.150 |
Why?
|
Databases, Factual | 5 | 2018 | 7729 | 0.150 |
Why?
|
Multicenter Studies as Topic | 3 | 2023 | 1677 | 0.150 |
Why?
|
Observer Variation | 3 | 2014 | 2593 | 0.150 |
Why?
|
Anterior Eye Segment | 1 | 2018 | 152 | 0.150 |
Why?
|
Leprostatic Agents | 2 | 2006 | 14 | 0.140 |
Why?
|
Risk Assessment | 10 | 2020 | 23338 | 0.140 |
Why?
|
Odds Ratio | 3 | 2014 | 9849 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2020 | 3479 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 541 | 0.140 |
Why?
|
Eye Infections, Fungal | 1 | 2017 | 110 | 0.140 |
Why?
|
Photography | 4 | 2022 | 520 | 0.130 |
Why?
|
Retina | 3 | 2022 | 2616 | 0.130 |
Why?
|
Conjunctivitis | 2 | 2014 | 158 | 0.130 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 25043 | 0.130 |
Why?
|
Injections, Intraocular | 1 | 2014 | 30 | 0.120 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 745 | 0.120 |
Why?
|
HIV | 2 | 2020 | 1604 | 0.120 |
Why?
|
Keratitis | 1 | 2017 | 268 | 0.120 |
Why?
|
Cytomegalovirus | 3 | 2023 | 732 | 0.120 |
Why?
|
Intraoperative Complications | 1 | 2021 | 1198 | 0.120 |
Why?
|
Lens Implantation, Intraocular | 2 | 2014 | 192 | 0.120 |
Why?
|
Infant | 8 | 2021 | 35136 | 0.120 |
Why?
|
Metformin | 1 | 2021 | 835 | 0.120 |
Why?
|
Maryland | 2 | 2005 | 276 | 0.120 |
Why?
|
Administration, Oral | 6 | 2020 | 3913 | 0.120 |
Why?
|
Necrosis | 1 | 2018 | 1643 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 9959 | 0.110 |
Why?
|
Time Factors | 11 | 2020 | 40075 | 0.110 |
Why?
|
Retinal Neovascularization | 1 | 2015 | 244 | 0.110 |
Why?
|
Quality of Life | 7 | 2017 | 12804 | 0.110 |
Why?
|
Viral Load | 4 | 2014 | 3299 | 0.110 |
Why?
|
Retinal Perforations | 1 | 2014 | 131 | 0.110 |
Why?
|
Reproducibility of Results | 8 | 2022 | 19905 | 0.110 |
Why?
|
Filtering Surgery | 2 | 2003 | 35 | 0.100 |
Why?
|
Fluoroquinolones | 1 | 2014 | 310 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2007 | 4386 | 0.100 |
Why?
|
Drug Therapy, Combination | 9 | 2020 | 6489 | 0.100 |
Why?
|
Anti-Infective Agents | 1 | 1999 | 972 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2019 | 1401 | 0.100 |
Why?
|
Forecasting | 1 | 2020 | 2951 | 0.090 |
Why?
|
Aging | 3 | 2017 | 8664 | 0.090 |
Why?
|
Delivery of Health Care | 4 | 2021 | 5319 | 0.090 |
Why?
|
Suppuration | 1 | 2009 | 56 | 0.090 |
Why?
|
Cost-Benefit Analysis | 2 | 2014 | 5391 | 0.090 |
Why?
|
Recurrence | 5 | 2015 | 8340 | 0.090 |
Why?
|
Population Surveillance | 1 | 2020 | 2616 | 0.090 |
Why?
|
Australia | 3 | 2017 | 1170 | 0.090 |
Why?
|
Biomedical Research | 2 | 2018 | 3309 | 0.090 |
Why?
|
Capillary Permeability | 1 | 2013 | 798 | 0.090 |
Why?
|
Optic Nerve Diseases | 1 | 2013 | 327 | 0.090 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2004 | 3336 | 0.090 |
Why?
|
Proportional Hazards Models | 5 | 2021 | 12354 | 0.080 |
Why?
|
Data Collection | 1 | 2018 | 3341 | 0.080 |
Why?
|
Tuberculosis | 1 | 2021 | 1912 | 0.080 |
Why?
|
Asia, Southeastern | 2 | 2018 | 111 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2759 | 0.080 |
Why?
|
Anesthesia, Local | 2 | 2001 | 275 | 0.080 |
Why?
|
Retinal Vein | 1 | 2008 | 47 | 0.080 |
Why?
|
Vitamin D Deficiency | 1 | 2018 | 1343 | 0.080 |
Why?
|
Health Surveys | 4 | 2012 | 4037 | 0.080 |
Why?
|
Postoperative Care | 1 | 2015 | 1486 | 0.080 |
Why?
|
Pattern Recognition, Visual | 1 | 1994 | 824 | 0.080 |
Why?
|
Eye | 2 | 2022 | 729 | 0.080 |
Why?
|
Retinal Artery | 1 | 2008 | 111 | 0.080 |
Why?
|
Retinal Vessels | 1 | 2013 | 772 | 0.080 |
Why?
|
Infant, Newborn | 3 | 2023 | 25625 | 0.080 |
Why?
|
Sensitivity and Specificity | 4 | 2022 | 14722 | 0.070 |
Why?
|
Optic Disk | 1 | 2011 | 400 | 0.070 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5751 | 0.070 |
Why?
|
Hepatitis, Autoimmune | 1 | 2009 | 141 | 0.070 |
Why?
|
Perioperative Care | 1 | 2015 | 1002 | 0.070 |
Why?
|
Delphi Technique | 2 | 2020 | 778 | 0.070 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2274 | 0.070 |
Why?
|
Europe | 3 | 2018 | 3339 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3255 | 0.070 |
Why?
|
Indoles | 1 | 2014 | 1839 | 0.070 |
Why?
|
Preoperative Care | 1 | 2015 | 2250 | 0.070 |
Why?
|
Anti-HIV Agents | 5 | 2007 | 4256 | 0.070 |
Why?
|
Antirheumatic Agents | 1 | 2015 | 1339 | 0.060 |
Why?
|
Orbital Pseudotumor | 1 | 2005 | 42 | 0.060 |
Why?
|
Nephritis, Interstitial | 1 | 2006 | 156 | 0.060 |
Why?
|
Retinal Artery Occlusion | 1 | 2005 | 74 | 0.060 |
Why?
|
Cocaine-Related Disorders | 1 | 2008 | 460 | 0.060 |
Why?
|
Cytosine | 1 | 2006 | 216 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1938 | 0.060 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2014 | 2043 | 0.060 |
Why?
|
Chronic Disease | 3 | 2019 | 9146 | 0.060 |
Why?
|
Retinal Vein Occlusion | 1 | 2005 | 137 | 0.060 |
Why?
|
Pseudophakia | 1 | 2004 | 62 | 0.060 |
Why?
|
Silicone Oils | 1 | 2003 | 22 | 0.060 |
Why?
|
Aphakia, Postcataract | 1 | 2004 | 54 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8388 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2009 | 2242 | 0.060 |
Why?
|
Functional Laterality | 2 | 2005 | 2290 | 0.060 |
Why?
|
Risk | 2 | 2014 | 9687 | 0.060 |
Why?
|
Cost of Illness | 2 | 2018 | 1859 | 0.060 |
Why?
|
HIV Seronegativity | 1 | 2004 | 211 | 0.060 |
Why?
|
Radiography, Thoracic | 2 | 2020 | 1265 | 0.060 |
Why?
|
Anxiety Disorders | 1 | 2014 | 2690 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2012 | 1373 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6895 | 0.060 |
Why?
|
Aqueous Humor | 1 | 2023 | 161 | 0.060 |
Why?
|
Rural Population | 2 | 2010 | 2210 | 0.060 |
Why?
|
Injections | 1 | 2006 | 840 | 0.060 |
Why?
|
Morbidity | 1 | 2008 | 1769 | 0.050 |
Why?
|
Acyclovir | 1 | 2023 | 272 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2021 | 15295 | 0.050 |
Why?
|
Cornea | 1 | 2011 | 1524 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6538 | 0.050 |
Why?
|
Herpesvirus 3, Human | 1 | 2023 | 204 | 0.050 |
Why?
|
Consensus | 2 | 2022 | 2959 | 0.050 |
Why?
|
Fundus Oculi | 2 | 2004 | 473 | 0.050 |
Why?
|
Arthritis, Reactive | 1 | 2021 | 19 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2014 | 1683 | 0.050 |
Why?
|
Comorbidity | 2 | 2013 | 10388 | 0.050 |
Why?
|
Tissue Donors | 2 | 2021 | 2240 | 0.050 |
Why?
|
Health Care Costs | 3 | 2014 | 3209 | 0.050 |
Why?
|
Polymyalgia Rheumatica | 1 | 2021 | 54 | 0.050 |
Why?
|
Neuropsychological Tests | 1 | 1994 | 6993 | 0.050 |
Why?
|
Trabeculectomy | 1 | 2002 | 160 | 0.050 |
Why?
|
Keratoplasty, Penetrating | 1 | 2021 | 155 | 0.050 |
Why?
|
Acute Disease | 3 | 2023 | 7149 | 0.050 |
Why?
|
Economics, Pharmaceutical | 1 | 2001 | 87 | 0.050 |
Why?
|
Anti-Bacterial Agents | 2 | 2019 | 7181 | 0.050 |
Why?
|
Onchocerciasis, Ocular | 1 | 2019 | 7 | 0.050 |
Why?
|
Epiretinal Membrane | 1 | 2020 | 68 | 0.050 |
Why?
|
Exudates and Transudates | 1 | 2020 | 172 | 0.040 |
Why?
|
Cause of Death | 2 | 2008 | 3584 | 0.040 |
Why?
|
Photometry | 1 | 2019 | 58 | 0.040 |
Why?
|
Spondylitis, Ankylosing | 1 | 2021 | 156 | 0.040 |
Why?
|
Herpesviridae Infections | 1 | 2021 | 277 | 0.040 |
Why?
|
Simplexvirus | 1 | 2023 | 802 | 0.040 |
Why?
|
Measles | 1 | 2021 | 168 | 0.040 |
Why?
|
Asia, Central | 1 | 2018 | 12 | 0.040 |
Why?
|
Tuberculin Test | 1 | 2020 | 214 | 0.040 |
Why?
|
Oceania | 1 | 2018 | 17 | 0.040 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2021 | 365 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3507 | 0.040 |
Why?
|
Africa, Northern | 1 | 2018 | 82 | 0.040 |
Why?
|
Health Status | 1 | 2012 | 4034 | 0.040 |
Why?
|
Atrophy | 1 | 2023 | 1583 | 0.040 |
Why?
|
Drug Administration Routes | 1 | 2018 | 153 | 0.040 |
Why?
|
Evidence-Based Medicine | 4 | 2003 | 3610 | 0.040 |
Why?
|
Pigment Epithelium of Eye | 1 | 1999 | 220 | 0.040 |
Why?
|
Policy | 1 | 2022 | 508 | 0.040 |
Why?
|
Middle East | 1 | 2018 | 219 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 930 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5535 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 8642 | 0.040 |
Why?
|
Photoreceptor Cells | 1 | 1999 | 244 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2003 | 820 | 0.040 |
Why?
|
Vitrectomy | 2 | 2015 | 365 | 0.040 |
Why?
|
Age Factors | 2 | 2012 | 18370 | 0.040 |
Why?
|
HIV Protease Inhibitors | 1 | 2000 | 430 | 0.040 |
Why?
|
Prognosis | 3 | 2013 | 29063 | 0.040 |
Why?
|
Health Status Indicators | 1 | 2003 | 969 | 0.040 |
Why?
|
Glaucoma, Open-Angle | 1 | 2004 | 706 | 0.040 |
Why?
|
Registries | 2 | 2023 | 8089 | 0.040 |
Why?
|
Anesthesia, Conduction | 1 | 2000 | 238 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 724 | 0.040 |
Why?
|
Anesthetics, Local | 2 | 2001 | 985 | 0.040 |
Why?
|
Giant Cell Arteritis | 1 | 2021 | 292 | 0.040 |
Why?
|
Vasculitis | 1 | 2021 | 519 | 0.040 |
Why?
|
Patient Care | 1 | 2022 | 640 | 0.040 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2000 | 615 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2005 | 2418 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1506 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5510 | 0.030 |
Why?
|
Sarcoidosis | 1 | 2021 | 506 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 1999 | 13695 | 0.030 |
Why?
|
Lasers | 1 | 2019 | 952 | 0.030 |
Why?
|
Developed Countries | 1 | 2018 | 437 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 924 | 0.030 |
Why?
|
Depression | 1 | 2014 | 7766 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5686 | 0.030 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7279 | 0.030 |
Why?
|
Presbyopia | 1 | 1994 | 9 | 0.030 |
Why?
|
Disease Progression | 4 | 2004 | 13284 | 0.030 |
Why?
|
Health Expenditures | 1 | 2007 | 2348 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 1518 | 0.030 |
Why?
|
Healthcare Disparities | 1 | 2009 | 3158 | 0.030 |
Why?
|
HLA-B27 Antigen | 1 | 2013 | 76 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2014 | 315 | 0.030 |
Why?
|
Insurance Claim Review | 1 | 2018 | 720 | 0.030 |
Why?
|
Smoking | 1 | 2010 | 8987 | 0.030 |
Why?
|
Psoriasis | 1 | 2021 | 898 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2023 | 2038 | 0.030 |
Why?
|
Orientation | 1 | 1994 | 327 | 0.030 |
Why?
|
Discrimination Learning | 1 | 1994 | 280 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2009 | 5137 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2008 | 13989 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2014 | 6365 | 0.030 |
Why?
|
Myopia | 1 | 1994 | 254 | 0.020 |
Why?
|
Axial Length, Eye | 1 | 2011 | 31 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2017 | 1970 | 0.020 |
Why?
|
Dacarbazine | 1 | 2014 | 566 | 0.020 |
Why?
|
Multivariate Analysis | 3 | 2014 | 12245 | 0.020 |
Why?
|
Immune System | 2 | 2006 | 805 | 0.020 |
Why?
|
Causality | 2 | 2010 | 1275 | 0.020 |
Why?
|
Biological Products | 1 | 2019 | 860 | 0.020 |
Why?
|
Body Weights and Measures | 1 | 2011 | 211 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 627 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1880 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20129 | 0.020 |
Why?
|
Quality Control | 2 | 2004 | 841 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 29786 | 0.020 |
Why?
|
United States Agency for Healthcare Research and Quality | 1 | 2009 | 92 | 0.020 |
Why?
|
Dry Eye Syndromes | 1 | 2014 | 386 | 0.020 |
Why?
|
Family | 1 | 2020 | 3147 | 0.020 |
Why?
|
Rural Health | 1 | 2010 | 305 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2104 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 601 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2002 | 7913 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2214 | 0.020 |
Why?
|
Eligibility Determination | 1 | 2011 | 403 | 0.020 |
Why?
|
Transportation | 1 | 2009 | 214 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2205 | 0.020 |
Why?
|
Reference Values | 1 | 1994 | 4982 | 0.020 |
Why?
|
Uveal Diseases | 1 | 2006 | 45 | 0.020 |
Why?
|
Decision Making | 1 | 2020 | 3887 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2021 | 2425 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2011 | 681 | 0.020 |
Why?
|
Logistic Models | 1 | 2021 | 13408 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2009 | 421 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4933 | 0.020 |
Why?
|
Recovery of Function | 2 | 2006 | 2925 | 0.020 |
Why?
|
Indomethacin | 1 | 2006 | 332 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 3923 | 0.020 |
Why?
|
DNA, Viral | 2 | 2003 | 2225 | 0.020 |
Why?
|
Psychomotor Performance | 1 | 1994 | 1901 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2014 | 2133 | 0.020 |
Why?
|
Arthritis, Rheumatoid | 1 | 2021 | 3712 | 0.020 |
Why?
|
Contrast Sensitivity | 1 | 2007 | 244 | 0.020 |
Why?
|
HIV-1 | 1 | 2003 | 6939 | 0.020 |
Why?
|
Uganda | 1 | 2010 | 1243 | 0.020 |
Why?
|
Bacteriological Techniques | 1 | 2006 | 277 | 0.020 |
Why?
|
China | 1 | 2011 | 2248 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6770 | 0.020 |
Why?
|
Vitamin D | 1 | 2018 | 3223 | 0.020 |
Why?
|
Prostheses and Implants | 1 | 2011 | 1387 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5524 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2010 | 2715 | 0.010 |
Why?
|
Mitomycin | 1 | 2002 | 259 | 0.010 |
Why?
|
Health Services Research | 1 | 2009 | 1836 | 0.010 |
Why?
|
Urban Population | 1 | 2010 | 2021 | 0.010 |
Why?
|
Laser Coagulation | 1 | 2003 | 326 | 0.010 |
Why?
|
Urine | 1 | 2003 | 370 | 0.010 |
Why?
|
Autonomic Nerve Block | 1 | 2001 | 72 | 0.010 |
Why?
|
Health Resources | 1 | 2007 | 911 | 0.010 |
Why?
|
Epidemiologic Studies | 1 | 2004 | 676 | 0.010 |
Why?
|
Blood | 1 | 2003 | 598 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2013 | 3327 | 0.010 |
Why?
|
Syndrome | 1 | 2006 | 3251 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 13881 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 2872 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2014 | 11031 | 0.010 |
Why?
|
Hemoglobins | 1 | 2005 | 1534 | 0.010 |
Why?
|
HIV Reverse Transcriptase | 1 | 2000 | 213 | 0.010 |
Why?
|
Patient Selection | 1 | 2011 | 4215 | 0.010 |
Why?
|
Software | 1 | 2013 | 4443 | 0.010 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2002 | 640 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2003 | 847 | 0.010 |
Why?
|
Insurance Coverage | 1 | 2009 | 1901 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1619 | 0.010 |
Why?
|
Antigens, Viral | 1 | 2002 | 1035 | 0.010 |
Why?
|
Orbit | 1 | 2001 | 426 | 0.010 |
Why?
|
Ultrasonography | 1 | 2011 | 5985 | 0.010 |
Why?
|
Placebos | 1 | 2002 | 1676 | 0.010 |
Why?
|
RNA, Viral | 1 | 2005 | 2902 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2014 | 10180 | 0.010 |
Why?
|
Conscious Sedation | 1 | 2000 | 528 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15540 | 0.010 |
Why?
|
Pain Measurement | 1 | 2001 | 3420 | 0.010 |
Why?
|
Pain, Postoperative | 1 | 2001 | 1643 | 0.010 |
Why?
|
Health Policy | 1 | 2001 | 2661 | 0.010 |
Why?
|